CAR Density Influences Antitumoral Efficacy of BCMA CAR T cells

European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma

Redirection of CAR-T Cell Cytotoxicity Using Metabolic Glycan Labeling with Unnatural Sugars

Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma - ScienceDirect

New directions in chimeric antigen receptor T cell [CAR‐T] therapy and related flow cytometry - Maryamchik - 2020 - Cytometry Part B: Clinical Cytometry - Wiley Online Library

Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies. - Abstract - Europe PMC

State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation

Frontiers The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice

European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma

Rohin I. on LinkedIn: CAR density influences antitumoral efficacy of BCMA CAR T cells and…

CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome

Mechanisms of Resistance and Treatment of Relapse after CAR T-cell Therapy for Large B-cell Lymphoma and Multiple Myeloma - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and

CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome

CAR Density Influences Antitumoral Efficacy of BCMA CAR T cells and Correlates with Clinical Outcome

Small-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies

Biology of CAR-T Cells